Back

Tekla Life Sciences Investors

Ticker: HQL ISIN: US87911K1007
Add to portfolio Portfolio analysis in 2min
Stock Small-cap Dividend payer Trading above 200-day average Near 52-week high
Market cap
$602.99M
P/E
2.94
Forward P/E
0.00
Profit margin
178.57%
Revenue growth QoQ
-60.80%
Div. yield
9.77%
Beta
0.71
$19.98 1.99%
Price as of 2026-09-22 · NYSE

Performance by timeframe

Rolling returns
1 Month -7.29%
6 Months +27.23%
1 Year +60.15%
5 Years +10.32% p.a.+63.37%
10 Years +10.85% p.a.+179.84%
Since inception +10.43% p.a.+1,090.56%
Calendar year returns
YTD +30.67%
2025 +45.48%
2024 +11.03%
2023 +4.23%
2022 -19.21%
2021 +5.52%

Key stats

Market cap
602.99M
P/E
2.94
Dividend yield
9.77%
Beta
0.71
52-week range
11.48 - 21.32
50-day MA
18.42
200-day MA
17.28
Section 1

Business overview

Company profile data from fundamentals.

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Sector Financial Services
Industry Asset Management
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 41.43%
ROA -0.61%
Profit margin 178.57%
Operating margin -5.17%
PEG ratio 0.00
Revenue/share TTM 0.04
Revenue TTM 1.11M
Gross profit TTM 1.11M
Beta 0.71

Valuation

Trailing P/E 2.94
Forward P/E 0.00
P/B 1.06
P/S 543.36
EV/EBITDA 0.00
EV/Revenue 2.99
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 0.00
Quarterly earnings growth 2.59%
Revenue TTM 1.11M
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 9.77%
Dividend per share 1.9100
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 0.11

Details

Instrument metadata and source update timestamps.

Symbol HQL
Name Tekla Life Sciences Investors
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US87911K1007
Country USA
Code + exchange HQL.NYSE
Last price date 2026-07-22
Fundamentals updated 2026-07-23

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.